A clinical trial listing update dated August 26, 2026 describes a new study titled "Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency." The trial is registered under identifier NCT07786571. Its current status is listed as not yet recruiting, meaning participant enrollment has not begun. The phase for this study is listed as not applicable. The study focuses on patients with type 2 diabetes mellitus who also have moderate to severe chronic renal insufficiency, according to the registered title. No results, outcomes, or efficacy data have been reported for this trial at this stage. No enrollment numbers, timelines, or additional design details were provided in the available event data. This update reflects only the registration and current recruitment status of the study as listed. Insulin glargine, an approved compound often used in diabetes management, is referenced in connection with this therapeutic area but is not the subject of this specific trial listing. Readers interested in background on insulin glargine can consult the compound overview for further context.
Trial Update: Dorzagliatin Study in T2D With Renal Insufficiency Registered
See the full insulin glargine overview
Source: https://clinicaltrials.gov/study/NCT07786571